Abstract

Leucine-rich repeat kinase 2 (LRRK2) variants associated with Parkinson's disease (PD) and Crohn's disease lead to increased phosphorylation of its Rab substrates. While it has been recently shown that perturbations in cellular homeostasis including lysosomal damage can increase LRRK2 activity and localization to lysosomes, the molecular mechanisms by which LRRK2 activity is regulated have remained poorly defined. We performed a targeted siRNA screen to identify regulators of LRRK2 activity and identified Rab12 as a novel modulator of LRRK2-dependent phosphorylation of one of its substrates, Rab10. Using a combination of imaging and immunopurification methods to isolate lysosomes, we demonstrated that Rab12 is actively recruited to damaged lysosomes and leads to a local and LRRK2-dependent increase in Rab10 phosphorylation. PD-linked variants, including LRRK2 R1441G and VPS35 D620N, lead to increased recruitment of LRRK2 to the lysosome and a local elevation in lysosomal levels of pT73 Rab10. Together, these data suggest a conserved mechanism by which Rab12, in response to damage or expression of PD-associated variants, facilitates the recruitment of LRRK2 and phosphorylation of its Rab substrate(s) at the lysosome.

Data availability

All data generated or analyzed during this study are included in the manuscript and supporting files; source data files for western blots have been provided for all figures.

Article and author information

Author details

  1. Xiang Wang

    Denali Therapeutics, South San Francisco, United States
    Competing interests
    Xiang Wang, is an employee of Denali Therapeutics..
  2. Vitaliy V Bondar

    Denali Therapeutics, South San Francisco, United States
    Competing interests
    Vitaliy V Bondar, was an employees of Denali Therapeutics when these studies were conducted and is currently an employee of REGENEXBIO Inc..
  3. Oliver B Davis

    Denali Therapeutics, South San Francisco, United States
    Competing interests
    Oliver B Davis, is an employee of Denali Therapeutics..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3622-8651
  4. Michael T Maloney

    Denali Therapeutics, South San Francisco, United States
    Competing interests
    Michael T Maloney, is an employee of Denali Therapeutics..
  5. Maayan Agam

    Denali Therapeutics, South San Francisco, United States
    Competing interests
    Maayan Agam, is an employee of Denali Therapeutics..
  6. Marcus Y Chin

    Denali Therapeutics, South San Francisco, United States
    Competing interests
    Marcus Y Chin, is an employee of Denali Therapeutics..
  7. Audrey Cheuk-Nga Ho

    Denali Therapeutics, South San Francisco, United States
    Competing interests
    Audrey Cheuk-Nga Ho, was an employee of Denali Therapeutics when these studies were conducted and is currently an employee of Cellares..
  8. Rajarshi Ghosh

    Denali Therapeutics, South San Francisco, United States
    Competing interests
    Rajarshi Ghosh, is an employee of Denali Therapeutics..
  9. Dara E Leto

    Denali Therapeutics, South San Francisco, United States
    Competing interests
    Dara E Leto, is an employee of Denali Therapeutics..
  10. David Joy

    Denali Therapeutics, South San Francisco, United States
    Competing interests
    David Joy, is an employee of Denali Therapeutics..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9941-9538
  11. Meredith EK Calvert

    Denali Therapeutics, South San Francisco, United States
    Competing interests
    Meredith EK Calvert, is an employee of Denali Therapeutics..
  12. Joseph W Lewcock

    Denali Therapeutics, South San Francisco, United States
    Competing interests
    Joseph W Lewcock, is an employee of Denali Therapeutics..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3012-7881
  13. Gilbert Di Paolo

    Denali Therapeutics, South San Francisco, United States
    Competing interests
    Gilbert Di Paolo, is an employee of Denali Therapeutics..
  14. Robert G Thorne

    Denali Therapeutics, South San Francisco, United States
    Competing interests
    Robert G Thorne, is an employee of Denali Therapeutics..
  15. Zachary K Sweeney

    Denali Therapeutics, South San Francisco, United States
    Competing interests
    Zachary K Sweeney, was an employee of Denali Therapeutics when these studies were conducted and is currently an employee of Interline Therapeutics Inc..
  16. Anastasia G Henry

    Denali Therapeutics, South San Francisco, United States
    For correspondence
    henry@dnli.com
    Competing interests
    Anastasia G Henry, is an employee of Denali Therapeutics..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8124-5477

Funding

No external funding was received for this work.

Reviewing Editor

  1. Shaeri Mukherjee, University of California, San Francisco, United States

Version history

  1. Preprint posted: February 22, 2023 (view preprint)
  2. Received: February 24, 2023
  3. Accepted: October 23, 2023
  4. Accepted Manuscript published: October 24, 2023 (version 1)
  5. Version of Record published: December 8, 2023 (version 2)

Copyright

© 2023, Wang et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,692
    views
  • 484
    downloads
  • 7
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Xiang Wang
  2. Vitaliy V Bondar
  3. Oliver B Davis
  4. Michael T Maloney
  5. Maayan Agam
  6. Marcus Y Chin
  7. Audrey Cheuk-Nga Ho
  8. Rajarshi Ghosh
  9. Dara E Leto
  10. David Joy
  11. Meredith EK Calvert
  12. Joseph W Lewcock
  13. Gilbert Di Paolo
  14. Robert G Thorne
  15. Zachary K Sweeney
  16. Anastasia G Henry
(2023)
Rab12 is a regulator of LRRK2 and its activation by damaged lysosomes
eLife 12:e87255.
https://doi.org/10.7554/eLife.87255

Share this article

https://doi.org/10.7554/eLife.87255

Further reading

    1. Cell Biology
    2. Computational and Systems Biology
    Trine Line Hauge Okholm, Andreas Bjerregaard Kamstrup ... Christian Kroun Damgaard
    Research Article

    Circular RNAs represent a class of endogenous RNAs that regulate gene expression and influence cell biological decisions with implications for the pathogenesis of several diseases. Here, we disclose a novel gene-regulatory role of circHIPK3 by combining analyses of large genomics datasets and mechanistic cell biological follow-up experiments. Using time-course depletion of circHIPK3 and specific candidate RNA-binding proteins, we identify several perturbed genes by RNA sequencing analyses. Expression-coupled motif analyses identify an 11-mer motif within circHIPK3, which also becomes enriched in genes that are downregulated upon circHIPK3 depletion. By mining eCLIP datasets and combined with RNA immunoprecipitation assays, we demonstrate that the 11-mer motif constitutes a strong binding site for IGF2BP2 in bladder cancer cell lines. Our results suggest that circHIPK3 can sequester IGF2BP2 as a competing endogenous RNA (ceRNA), leading to target mRNA stabilization. As an example of a circHIPK3-regulated gene, we focus on the STAT3 mRNA as a specific substrate of IGF2BP2 and validate that manipulation of circHIPK3 regulates IGF2BP2-STAT3 mRNA binding and, thereby, STAT3 mRNA levels. Surprisingly, absolute copy number quantifications demonstrate that IGF2BP2 outnumbers circHIPK3 by orders of magnitude, which is inconsistent with a simple 1:1 ceRNA hypothesis. Instead, we show that circHIPK3 can nucleate multiple copies of IGF2BP2, potentially via phase separation, to produce IGF2BP2 condensates. Our results support a model where a few cellular circHIPK3 molecules can induce IGF2BP2 condensation, thereby regulating key factors for cell proliferation.

    1. Cell Biology
    2. Computational and Systems Biology
    N Suhas Jagannathan, Javier Yu Peng Koh ... Lisa Tucker-Kellogg
    Research Article

    Bats have unique characteristics compared to other mammals, including increased longevity and higher resistance to cancer and infectious disease. While previous studies have analyzed the metabolic requirements for flight, it is still unclear how bat metabolism supports these unique features, and no study has integrated metabolomics, transcriptomics, and proteomics to characterize bat metabolism. In this work, we performed a multi-omics data analysis using a computational model of metabolic fluxes to identify fundamental differences in central metabolism between primary lung fibroblast cell lines from the black flying fox fruit bat (Pteropus alecto) and human. Bat cells showed higher expression levels of Complex I components of electron transport chain (ETC), but, remarkably, a lower rate of oxygen consumption. Computational modeling interpreted these results as indicating that Complex II activity may be low or reversed, similar to an ischemic state. An ischemic-like state of bats was also supported by decreased levels of central metabolites and increased ratios of succinate to fumarate in bat cells. Ischemic states tend to produce reactive oxygen species (ROS), which would be incompatible with the longevity of bats. However, bat cells had higher antioxidant reservoirs (higher total glutathione and higher ratio of NADPH to NADP) despite higher mitochondrial ROS levels. In addition, bat cells were more resistant to glucose deprivation and had increased resistance to ferroptosis, one of the characteristics of which is oxidative stress. Thus, our studies revealed distinct differences in the ETC regulation and metabolic stress responses between human and bat cells.